Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$22.06

2.26 (11.41%)

, DBVT

DBV Technologies

$9.72

0.75 (8.36%)

08:28
09/11/19
09/11
08:28
09/11/19
08:28

FDA posts briefing docs for Aimmune panel, brings up allergic reactions

The FDA posted breifing documents ahead of Friday's panel meeting for Aimmune Therapeutics' (AIMT) peanut allergy treatment Palforzia. The FDA states, "Palforzia treated subjects in the pediatric safety population reported an increased number of allergic reactions, including systemic allergic reactions, compared to placebo-treated subjects. A total of 9.4% subjects taking Palforzia had a systemic allergic reaction during initial dose escalation and updosing compared to 3.8% of placebo subjects. This imbalance was seen during maintenance as well with 8.7% of Palforzia treated patients having a systemic allergic reaction compared to 1.7% of placebo-treated subjects. During the maintenance period, 7.7% of Palforzia treated subjects used epinephrine compared to 3.4% in the placebo group. Twelve subjects treated with Palforzia were diagnosed with eosinophilic esophagitis (EoE) in the entire clinical development program while no subjects in the placebo group of the controlled safety population received a diagnosis of EoE. Similar safety data are seen in the adult population with respect to systemic allergic reactions." DBV Technologies (DBVT) is also developing a treatment for peanut allergy. Shares of Aimmune, after rallying 12% yesterday, are down 3% to $21.43 in premarket trading. Reference Link

AIMT

Aimmune

$22.06

2.26 (11.41%)

DBVT

DBV Technologies

$9.72

0.75 (8.36%)

  • 13

    Sep

AIMT Aimmune
$22.06

2.26 (11.41%)

08/05/19
PIPR
08/05/19
NO CHANGE
Target $60
PIPR
Overweight
Aimmune FDA panel could break downward share trend, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on Aimmune Therapeutics with a $60 price target after traveling with management. Despite the recent share performance, new money investment in this name, "even in the teeth of the current trend," may make sense, Raymond tells investors in a research note. The analyst thinks the company's September 13 FDA panel meeting for AR101 in peanut allergy "could serve as the catalyst to break the stock's downward trend." Further, Raymond feels "increasingly confident" in a "strong" commercial launch for AR101. Investors "who can look past the scary technicals can be rewarded here," he says.
08/05/19
HCWC
08/05/19
NO CHANGE
Target $25
HCWC
Buy
H.C. Wainwright reiterates Buy on DBV ahead of expected BLA resubmission
H.C. Wainwright analyst Andrew Fein says that as DBV Technologie (DBVT) moves forward towards an anticipated Biologics License Application resubmission for Viaskin Peanut in Q3, he continues to be supportive of the overall value, safety, and efficacy of the Viaskin Peanut program. Following organizational updates, a "straightforward BLA resubmission could refresh investors' confidence in management, while addressing the regulatory overhang," Fein tells investors in a research note. He reiterates a Buy rating on DBV shares with a $25 price target. His confidence in the Viaskin Peanut program has been based on "exceptional safety and sufficient efficacy to manage the risk of accidental exposure." The analyst believes these properties differentiate Viaskin Peanut from the peanut oral immunotherapy being developed by Aimmune (AIMT).
08/09/19
RBCM
08/09/19
NO CHANGE
Target $50
RBCM
Outperform
Aimmune price target lowered to $50 from $58 at RBC Capital
RBC Capital analyst Kennen MacKay lowered his price target on Aimmune to $50 after its Q2 earnings miss, also reducing his launch expectations for AR101 based on the analysis of the "recent comparable drug launches into indications with a similar unmet need." The analyst still keeps his Outperform rating on the stock and sees AR101 as well positioned to "disrupt and build the peanut allergy desensitization market".
09/09/19
BARD
09/09/19
NO CHANGE
Target $64
BARD
Outperform
Aimmune added as a Fresh Pick, AdCom a binary event, says Baird
Baird analyst Brian Skorney Added Aimmune as a Fresh Pick ahead of Friday's AdCom event. The analyst said it will be mid-week briefing documents followed by Friday's meeting which he expects to be a binary event. He believes it should be a positive catalyst which could yield a 20-30% upside from its current price and he noted AR101 has shown robust efficacy in increasing the amount of peanut protein tolerated by patients during it PALISADE trial. Skorney reiterated his Outperform rating and $64 price target on Aimmune shares.
DBVT DBV Technologies
$9.72

0.75 (8.36%)

06/17/19
GSCO
06/17/19
INITIATION
Target $14
GSCO
Buy
DBV Technologies initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Graig Suvannavejh started DBV Technologies (DBVT) with a Buy rating and $14 price target. DBVT is a late-stage specialty biotech company, with a proprietary technology platform that could be used to treat a range of food allergies, Suvannavejh tells investors in a research note. The analyst sees 66% upside from current share levels given the potential catalysts over the next 18 months, which include the Biologics License Applications re-filing in Q3 and FDA acceptance in Q4, a potential panel hearing in mid-2020, and likely final U.S. approval by the end of 2020. Suvannavejh sees an 85% probability of success for DBV's Viaskin Peanut and views the treatment as a more compelling option versus Aimmune's (AIMT) AR101 on overall safety and product presentation profiles.
06/17/19
06/17/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. DBV Technologies (DBVT) initiated with a Buy at Goldman Sachs. 2. Amicus (FOLD) initiated with a Buy at H.C. Wainwright. 3. Viper Energy (VNOM) initiated with a Buy at SunTrust. 4. GNC Holdings (GNC) initiated with a Hold at Jefferies. 5. Eventbrite (EB) initiated with an Outperform at William Blair. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/12/19
WEDB
07/12/19
NO CHANGE
Target $79
WEDB
Outperform
Aimmune selloff on ICER report overdone, says Wedbush
Wedbush analyst Liana Moussatos views the selloff yesterday in shares of Aimmune Therapeutics as overdone. The Institute for Clinical and Economic Review on Wednesday released a final report on emerging desensitization treatments for peanut allergy and compared the clinical effectiveness and value of Aimmune's AR101, DBV Technologies' (DBVT) Viaskin and non-commercialized oral immunotherapy for treatment of peanut allergy, Moussatos tells investors in a research note. However, the ICER report excluded long-term desensitization and patient quality-of-life results for AR101 and hence failed to recognize the full value of AR101 immunotherapy for peanut allergy, says the analyst. She sees an "excellent entry point" into Aimmune shares following yesterday's selloff and reiterates an Outperform rating on the name wih a $79 price target.

TODAY'S FREE FLY STORIES

OSTK

Overstock.com

$16.19

-1.41 (-8.01%)

09:03
09/19/19
09/19
09:03
09/19/19
09:03
Hot Stocks
Overstock.com down 9.3% in pre-market after founder Byrne sold 4.7M share stake »

Shares of Overstock.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MNKD

MannKind

$1.33

-0.055 (-3.97%)

09:03
09/19/19
09/19
09:03
09/19/19
09:03
Hot Stocks
MannKind presents data from one-year study of Afrezza Inhalation Powder »

MannKind announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

NAV

Navistar

$29.09

-0.08 (-0.27%)

09:02
09/19/19
09/19
09:02
09/19/19
09:02
Hot Stocks
Navistar to build new manufacturing facility in Texas »

Navistar announced it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AJG

Arthur J. Gallagher

$89.89

0.26 (0.29%)

09:00
09/19/19
09/19
09:00
09/19/19
09:00
Hot Stocks
Arthur J. Gallagher acquires Andrew Insurance Associates »

Arthur J. Gallagher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

09:00
09/19/19
09/19
09:00
09/19/19
09:00
General news
Fed's overnight repo was oversubscribed again »

Fed's overnight repo…

HOOK

Hookipa Pharma

$8.03

0.22 (2.82%)

08:59
09/19/19
09/19
08:59
09/19/19
08:59
Hot Stocks
Hookipa Pharma to present data on TheraT technology at CICON Conference »

HOOKIPA Pharma will…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

VBIV

VBI Vaccines

$0.67

-0.0482 (-6.68%)

08:58
09/19/19
09/19
08:58
09/19/19
08:58
Syndicate
VBI Vaccines 70M share Secondary priced at 50c »

Raymond James and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

CNC

Centene

$46.02

0.475 (1.04%)

, WCG

WellCare

$268.55

1.17 (0.44%)

08:57
09/19/19
09/19
08:57
09/19/19
08:57
Hot Stocks
Centene, WellCare announce state insurance department approvals for merger »

Centene (CNC) and…

CNC

Centene

$46.02

0.475 (1.04%)

WCG

WellCare

$268.55

1.17 (0.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 02

    Oct

  • 22

    Oct

  • 25

    Oct

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

GIII

G-III Apparel

$24.78

0.03 (0.12%)

08:56
09/19/19
09/19
08:56
09/19/19
08:56
Recommendations
G-III Apparel analyst commentary  »

G-III one of the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 25

    Sep

08:56
09/19/19
09/19
08:56
09/19/19
08:56
Conference/Events
The Federal Energy Regulatory Commission (FERC) to hold a meeting »

Open Commission Meeting…

T

AT&T

$36.77

-0.39 (-1.05%)

, FDX

FedEx

$150.91

-22.62 (-13.04%)

08:55
09/19/19
09/19
08:55
09/19/19
08:55
Options
Notable open interest changes for September 19th »

Wednesday's total…

T

AT&T

$36.77

-0.39 (-1.05%)

FDX

FedEx

$150.91

-22.62 (-13.04%)

BAC

Bank of America

$30.00

0.08 (0.27%)

ROKU

Roku

$129.79

-20.64 (-13.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Sep

  • 23

    Sep

  • 30

    Sep

  • 01

    Oct

  • 16

    Oct

  • 23

    Oct

  • 13

    Nov

  • 17

    Dec

08:55
09/19/19
09/19
08:55
09/19/19
08:55
Conference/Events
Morgan Stanley global autos analysts to hold an analyst/industry conference call »

European Autos &…

IHRT

iHeartMedia

$14.79

0.11 (0.75%)

08:53
09/19/19
09/19
08:53
09/19/19
08:53
Initiation
iHeartMedia initiated  »

B. Riley FBR starts…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 23

    Sep

PODD

Insulet

$148.04

3 (2.07%)

08:50
09/19/19
09/19
08:50
09/19/19
08:50
Conference/Events
Insulet participates in a conference call with SVB Leerink »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BMWYY

BMW

$0.00

(0.00%)

08:50
09/19/19
09/19
08:50
09/19/19
08:50
Periodicals
BMW to cut up to 6,000 jobs in Germany, Bloomberg reports »

BMW plans to cut up to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:50
09/19/19
09/19
08:50
09/19/19
08:50
General news
The 2k initial claims uptick to 208k »

The 2k initial claims…

08:50
09/19/19
09/19
08:50
09/19/19
08:50
General news
U.S. Q2 current account balance narrowed to -$128.2 B »

U.S. Q2 current account…

PPC

Pilgrim's Pride

$30.86

-0.39 (-1.25%)

08:49
09/19/19
09/19
08:49
09/19/19
08:49
Recommendations
Pilgrim's Pride analyst commentary  »

Pilgrim's Pride…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 13

    Nov

GIS

General Mills

$54.51

-0.52 (-0.94%)

08:48
09/19/19
09/19
08:48
09/19/19
08:48
Recommendations
General Mills analyst commentary  »

Operating gains at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 01

    Oct

NEOG

Neogen

$78.05

-0.71 (-0.90%)

08:48
09/19/19
09/19
08:48
09/19/19
08:48
Hot Stocks
Neogen partners with IGS to enhance Igenity Beef Profile »

Neogen has entered into a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Sep

  • 03

    Oct

  • 13

    Nov

PRSP

Perspecta

$26.02

0.015 (0.06%)

08:47
09/19/19
09/19
08:47
09/19/19
08:47
Hot Stocks
Perspecta Labs awarded $2.9M contract from CMG »

Perspecta announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

INSP

Inspire Medical

$64.41

0.14 (0.22%)

08:46
09/19/19
09/19
08:46
09/19/19
08:46
Conference/Events
Inspire Medical participates in a conference call with SVB Leerink »

Conference call with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EWW

iShares MSCI Mexico

$43.37

-0.4 (-0.91%)

, CGC

Canopy Growth

$28.82

0.42 (1.48%)

08:45
09/19/19
09/19
08:45
09/19/19
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

EWW

iShares MSCI Mexico

$43.37

-0.4 (-0.91%)

CGC

Canopy Growth

$28.82

0.42 (1.48%)

FSLY

Fastly

$28.53

0.285 (1.01%)

INSG

Inseego

$4.98

0.04 (0.81%)

PAYS

Paysign

$10.67

-0.57 (-5.07%)

PD

PagerDuty

$30.41

-0.125 (-0.41%)

UBER

Uber

$34.24

-0.04 (-0.12%)

TELL

Tellurian

$8.34

0.01 (0.12%)

UPRO

Uproar Inc

$57.03

0.055 (0.10%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

08:45
09/19/19
09/19
08:45
09/19/19
08:45
General news
U.S. Philly Fed index fell 4.8 points to 12.0 in September »

U.S. Philly Fed index…

RAMP

LiveRamp

$46.01

-0.4 (-0.86%)

08:44
09/19/19
09/19
08:44
09/19/19
08:44
Recommendations
LiveRamp analyst commentary  »

LiveRamp conference…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.